Market Cap
$7.4B
IONS
IONIS PHARMACEUTICALS INC
$43.41 ▼ -1.34%
Prev close $44.00Market cap$7.4B
ConsensusBuy
12-mo target$83.64 (+92.7%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (10 insiders)High Impact Filing (7/10)33 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on IONS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (78%)
Inst. Holders
50 funds
Inst. Value
$11.5B
Inst. Activity
33 buys / 17 sells
Insider Activity
$1.1M buy / $14.6M sell
Insider Net $
-$13.5M
Social Sentiment
60° Warm
SEC Reports
20
Price chart 30d -29.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 fda_pdufa
Sep 4, 2026 SEC PDUFA: IONS — bepirovirsen in chronic hepatitis B (CHB) — 2026-10-26
FDA target action date 2026-10-26 for IONS (IONIS PHARMACEUTICALS INC). Drug: bepirovirsen. Indicati
Ionis Pharmaceuticals announced that its partner Novartis reported the Phase 3 Lp(a)HORIZON study of pelacarsen did not
8-K — Impact 7/10
Ionis Pharmaceuticals announced FDA approval of ZANVASTRO (zilganersen) as the first and only disease-modifying treatmen
8-K — Impact 7/10
Sep 3, 2026 Event
ZANVASTRO
Original Approval — Type 1 - New Molecular Entity — INJECTION
Aug 31, 2026 Insider
O'NEIL PATRICK R. acquired 63 shares
EVP CLO & General Counsel @ $51.31 ($3.2K)
Aug 31, 2026 Insider
Birchler Brian acquired 58 shares
EVP, Corp and Development Ops @ $51.31 ($3.0K)
Aug 31, 2026 Insider
Aug 1, 2026 SEC Monia Brett P acquired 98 shares
Chief Executive Officer @ $51.31 ($5.0K)
Director Michael Hayden made two open-market purchases of IONS stock totaling $1.06M on July 30-31, 2026, at prices betw
INSIDER-BUY — Impact 4/10
Analyst ratings buy % +2.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
78% rate it Buy or better · 32 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 22, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Sep 15, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Sep 9, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Sep 8, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Sep 8, 2026 | Goldman Sachs | MAINTAIN | Neutral | 54% |
| Sep 8, 2026 | BMO Capital | MAINTAIN | Market Perform | 53% |
| Sep 8, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Sep 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 4, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 17 | 7 | 0 | 0 | 78% | |
| Aug 1, 2026 | 8 | 17 | 6 | 0 | 0 | 81% | |
| Jul 1, 2026 | 11 | 16 | 6 | 0 | 0 | 82% | |
| Jun 1, 2026 | 10 | 17 | 6 | 0 | 0 | 82% | |
| May 1, 2026 | 9 | 16 | 6 | 0 | 0 | 81% | |
| Apr 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Mar 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Feb 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% |
Price targets
Where 22 covering analysts think IONS trades over the next 12 months.
$83.64 +92.7% upside Strong Buy
Current$43.41 Low$54.00 Median$85.00 High$105.00 22 analysts
$54.00$105.00
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 4 bullish, 2 bearish, 2 mixed, 12 neutral · avg impact 4.3/10.
BEARISH8-K7/10
Ionis Pharmaceuticals announced that its partner Novartis reported the Phase 3 Lp(a)HORIZON study of
Sep 4, 2026
BULLISH8-K7/10
Ionis Pharmaceuticals announced FDA approval of ZANVASTRO (zilganersen) as the first and only diseas
Sep 4, 2026
NEUTRALINSIDER-BUY4/10
Director Michael Hayden made two open-market purchases of IONS stock totaling $1.06M on July 30-31,
Aug 1, 2026
MIXED8-K6/10
Ionis reported Q2 2026 revenue of $268M (vs. $190.1M consensus) and GAAP EPS of -$0.69, which is a m
Jul 29, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 26, 2026
fda_pdufa
PDUFA: IONS — bepirovirsen in chronic hepatitis B (CHB) — 2026-10-26
FDA target action date 2026-10-26 for IONS (IONIS PHARMACEUTICALS INC). Drug: bepirovirsen. Indication: chronic hepatitis B (CHB). NDA accepted for Pr
Sep 22, 2026
fda_pdufa
PDUFA: IONS — zilganersen in Alexander disease — 2026-09-22
FDA target action date 2026-09-22 for IONS (IONIS PHARMACEUTICALS INC). Drug: zilganersen. Indication: Alexander disease. PDUFA action date set for zi
Sep 10, 2026
Clinical Trial
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 10, 2026
clinical_trial_readout
T-90d Trial Readout: Donidalorsen (Phase 3)
Trial: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Sponsor: Ionis
Sep 8, 2026
Clinical Trial
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.92 | $-1.06–$-0.65 | -49.6% | +0.0% | 1↑ 5↓ | $0.2B | 8 |
| Next Q | $-0.89 | $-1.20–$-0.61 | 22.7% | +0.1% | 0↑ 5↓ | $0.2B | 8 |
| Current FY | $-2.70 | $-3.70–$-2.12 | -75.0% | -4.3% | 2↑ 1↓ | $0.9B | 10 |
| Next FY | $-1.11 | $-2.47–$0.60 | 58.8% | -5.5% | 3↑ 1↓ | $1.4B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.916 | — |
| 7d ago | $-0.916 | — |
| 30d ago | $-0.916 | — |
| 60d ago | $-0.806 | -0.111 |
| 90d ago | $-0.843 | -0.073 |
Institutional ownership
Which big funds own IONS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $11.5B total value (144,451,774 shares) as of 2026-Q2. Top holders: FMR, Capital, BlackRock,. Net buying activity: 33 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 24,631,956 | $2.0B | 17.0% | — |
| Capital World Investors | 21,669,226 | $1.7B | 15.0% | — |
| BlackRock, Inc. | 10,704,660 | $848.8M | 7.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7,859,529 | $623.2M | 5.4% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 7,651,415 | $606.7M | 5.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,211,497 | $571.8M | 5.0% | — |
| TWO SIGMA INVESTMENTS, LP | 6,252,342 | $495.7M | 4.3% | — |
| ROYAL BANK OF CANADA | 6,182,479 | $490.2M | 4.3% | ADD +62.6% |
| STATE STREET CORP | 4,334,848 | $343.7M | 3.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,584,024 | $294.8M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | ADD | 3,801,815 | 6,182,479 | +62.6% | $490.2M |
| Artisan Partners Limited Partnership | ADD | 2,058,308 | 2,640,024 | +28.3% | $209.3M |
| BARCLAYS PLC | DOUBLED | 289,874 | 1,603,136 | +453.0% | $127.1M |
| Polar Capital Holdings Plc | ADD | 829,511 | 1,454,021 | +75.3% | $115.3M |
| Alyeska Investment Group, L.P. | DOUBLED | 473,150 | 1,417,916 | +199.7% | $112.4M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | ADD | 785,281 | 1,300,392 | +65.6% | $103.1M |
| Capital International Investors | NEW | — | 823,764 | — | $65.3M |
| Neuberger Berman Group LLC | ADD | 443,272 | 633,533 | +42.9% | $50.2M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 305,549 | 559,414 | +83.1% | $44.4M |
| JANE STREET GROUP, LLC | DOUBLED | 191,818 | 503,647 | +162.6% | $39.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$13.5M — $1.1M bought, $14.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | J | 63 | $51.31 | $3.2K |
| Aug 31, 2026 | Birchler Brian | EVP, Corp and Development Ops | J | 58 | $51.31 | $3.0K |
| Aug 31, 2026 | Monia Brett P | Chief Executive Officer | J | 98 | $51.31 | $5.0K |
| Aug 31, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | J | 110 | $51.31 | $5.6K |
| Jul 31, 2026 | Hayden Michael R | Director | BUY | 5,000 | $51.60 | $258.0K |
| Jul 30, 2026 | Hayden Michael R | Director | BUY | 15,000 | $53.38 | $800.7K |
| Jul 15, 2026 | BERTHELSEN SPENCER R | Director | EXERCISE | 5,220 | — | — |
| Jul 15, 2026 | HERMAN JOAN E | Director | EXERCISE | 5,220 | — | — |
| Jul 15, 2026 | Reikes Peter N | Director | AWARD | 3,399 | — | — |
| Jul 15, 2026 | HANTSON LUDWIG | Director | AWARD | 3,399 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IONS.
Shares short
20,890,252
Settlement Sep 15, 2026
Change vs prior
-0.2%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈12.6%
Estimate — not % of float
All IONS filing & press-release reports (20)
- 8-K reportSep 4, 2026
- 8-K reportSep 4, 2026
- INSIDER-BUY reportAug 1, 2026
- 8-K reportJul 29, 2026
- 8-K reportJul 10, 2026
- CLUSTER reportJul 10, 2026
- CLUSTER reportJul 9, 2026
- 8-K reportJul 9, 2026
- CLUSTER reportJul 6, 2026
- CLUSTER reportJun 30, 2026
- CLUSTER reportJun 26, 2026
- 8-K reportJun 25, 2026
- CLUSTER reportJun 16, 2026
- 8-K reportJun 12, 2026
- 8-K reportJun 8, 2026
- 8-K reportMay 28, 2026
- CLUSTER reportMay 6, 2026
- 8-K reportApr 21, 2026
- CLUSTER reportApr 17, 2026
- 8-K reportFeb 25, 2026